Get the Stockscreener App
44.07
5.95%
-2.79
After Hours:
43.70
-0.37
-0.84%
Moderna Inc stock is traded at $44.07, with a volume of 10.94M.
It is down -5.95% in the last 24 hours and up +44.92% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$46.86
Open:
$45.98
24h Volume:
10.94M
Relative Volume:
0.90
Market Cap:
$17.22B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-5.0481
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-9.53%
1M Performance:
+44.92%
6M Performance:
+37.08%
1Y Performance:
+7.38%
1-Day Range:
$43.43
$46.34
1-Week Range:
$43.43
$51.18
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
44.07 | 18.31B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Announces Leadership Changes Amid Strategic Shift - GuruFocus
Moderna CMO Jacqueline Miller to step down - WKZO
Moderna announces departure of medical chief (MRNA:NASDAQ) - Seeking Alpha
Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating - marketscreener.com
Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026 - marketscreener.com
Moderna Vs. Novavax: 2 Pandemic Vaccine PioneersWhich Offers Better Value Today? (MRNA) - Seeking Alpha
Dr. David Berman to Join Moderna as Chief Development Officer - USA Today
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M - BioSpace
Moderna appoints David Berman as new chief development officer - Investing.com
Immunotherapy veteran David Berman to steer drug development at Moderna - Stock Titan
Moderna, Inc. $MRNA Stock Holdings Reduced by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - The Fayetteville Observer
Recordati partners with Moderna on rare disease treatment By Investing.com - Investing.com Canada
Recordati and Moderna Sign Global Agreement on mRNA Therapy for Rare Disease - marketscreener.com
Jim Cramer on Moderna: “We have to wait and see” - MSN
Moderna (MRNA) Partners with Recordati for mRNA-3927 Development and Marketing - GuruFocus
Moderna Collaborates With Recordati to Advance, Commercialize Investigational Therapy to Treat Metabolic Disorder - marketscreener.com
Recordati Announces Collaboration With Moderna For Mrna-3927 - TradingView
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA - marketscreener.com
Moderna partners with Recordati on rare disease therapy - Investing.com
RecordatiAnnounces Collaboration With Moderna For Mrna-3927 - TradingView
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927) - The Batesville Daily Guard
Rare metabolic disease drug mRNA-3927 draws up to $160M Moderna-Recordati pact - Stock Titan
Jim Cramer on Moderna: "We Have to Wait and See" - Finviz
Jim Cramer on Moderna: “We Have to Wait and See” - Insider Monkey
U.S. vaccine hesitancy could impact investment - Axios
Moderna holds a ‘garage sale’; Roche defends obesity drug data - Yahoo Finance
Moderna, Inc. $MRNA Shares Sold by Federated Hermes Inc. - MarketBeat
Moderna's Chief Medical Officer Resigns, New R&D Direction Announced - Intellectia AI
This Stock Is Already Up 58% This Year. Is It a Buy? - Finviz
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating - marketscreener.com
Moderna (MRNA) Leads Healthcare Stocks with Impressive Gains - GuruFocus
Top performing healthcare stocks in the past month (MRNA:NASDAQ) - Seeking Alpha
Moderna (NASDAQ:MRNA) Coverage Initiated at Barclays - MarketBeat
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More - BioSpace
Analyst Calls: Can Moderna Inc continue delivering strong returns2025 Year in Review & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Oncolytics Biotech Strengthens Leadership for Oncology Trials - Intellectia AI
US Stocks Recap: What are the future prospects of Moderna IncBuy Signal & Weekly High Conviction Ideas - baoquankhu1.vn
Moderna Partners with Recordati to Advance mRNA-3927 Development - Intellectia AI
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - The Motley Fool
Moderna (MRNA) stock slips; Feb. 13 earnings call is the next catalyst for the share price - TechStock²
Behind the Scenes of Moderna's Latest Options Trends - Benzinga
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 - Hastings Tribune
Aug Momentum: Is Moderna Inc a momentum stockJuly 2025 Levels & Capital Protection Trading Alerts - baoquankhu1.vn
Moderna shifts focus in response to US vaccine skepticism - medwatch.com
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities - oakridger.com
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - lansingstatejournal.com
Promising Biotech Stocks To Follow TodayJanuary 25th - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):